First Berlin Equity Research Raises Pharming Group NV Price Target to €2.60
I'm PortAI, I can summarize articles.
First Berlin Equity Research has raised the 12-month price target for Pharming Group NV from €2.40 to €2.60, maintaining a Buy recommendation. Analyst Simon Scholes noted a 27% increase in preliminary 2025 revenues to $376 million, exceeding company guidance. The report highlights upcoming clinical read-outs for leniolisib and the pivotal phase 2 study of KL1333, indicating a positive outlook for the company.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments